Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
Diabetes & Vascular Disease Research|December 14, 2020
Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME<sup>®</sup>Gisle Langslet, Bernard Zinman, Christoph Wanner, et al.
European Heart Journal|March 9, 2011
Factors influencing underutilization of evidence-based therapies in womenRaffaele Bugiardini, Andrew T Yan, Raymond T Yan, et al.
Diabetologia|May 20, 2018
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trialSubodh Verma, C David Mazer, David Fitchett, et al.
Critical Pathways in Cardiology|November 15, 2014
Pharmacodynamic and clinical implications of switching between P2Y12 receptor antagonists: considerations for practiceAkshay Bagai, Doson Chua, Eric A Cohen, et al.
Diabetologia|May 2, 2018
Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, et al.
American Heart Journal|August 15, 2002
Development and prognosis of non-Q-wave myocardial infarction in the thrombolytic eraShaun G Goodman, Aiala Barr, Anatoly Langer, et al.
CJC Open|July 19, 2024
Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME TrialAyodele Odutayo, Bernard Zinman, Christoph Wanner, et al.
European Heart Journal|September 11, 2019
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trialDavid Fitchett, Silvio E Inzucchi, Christoph Wanner, et al.
ESC Heart Failure|September 11, 2020
Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOMEPierpaolo Pellicori, Anne Pernille Ofstad, David Fitchett, et al.
Clinical Biochemistry|November 26, 2003
Do glycoprotein IIb/IIIa inhibitors interact with assays for myocardial necrosis?Warren J Cantor, Art Vandenbroucke, Bradley H Strauss, et al.
Pageof 10